The following Life Sciences practice note provides comprehensive and up to date legal information covering:
This Practice Note provides an overview of the Medicines and Medical Devices Act 2021 (MMDA 2021) which, in summary, makes provision about a Commissioner for Patient Safety in relation to human medicines and medical devices, enables the existing UK regulatory frameworks for medicines and medical devices to be updated following the end of the implementation period, consolidates the enforcement provisions on medical devices and allows the sharing of information on medical devices. The Practice Note outlines the legal context and the purposes of MMDA 2021, tracks the steps of its legislative procedure and examines the key provisions on human medicines, clinical trials and medical devices:
Background and purposes of the Medicines and Medical Devices Act 2021
Overview of the Medicines and Medical Devices Act 2021
Part 2—Human medicines
Part 4—Medical devices
Timeline of legislative procedure and commencement
A large part of the UK legal framework for medicinal products and medical devices originates from EU law (regulations and directives), which has been given effect and implemented in the UK through the European Communities Act 1972 (ECA 1972). ECA 1972 was repealed on exit day by the
Free trials are only available to individuals based in the UK
Complete all the fields above to proceed to the next step.
**Trials are provided to all LexisPSL and LexisLibrary content, excluding Practice Compliance, Practice Management and Risk and Compliance, subscription packages are tailored to your specific needs. To discuss trialling these LexisPSL services please email customer service via our online form. Free trials are only available to individuals based in the UK. We may terminate this trial at any time or decide not to give a trial, for any reason. Trial includes one question to LexisAsk during the length of the trial.
To view the latest version of this document and thousands of others like it, sign-in to LexisPSL or register for a free trial.
Existing user? Sign-in
Parliamentary committeesIP COMPLETION DAY: 11pm (GMT) on 31 December 2020 marks the end of the Brexit transition/implementation period entered into following the UK’s withdrawal from the EU. At this point in time (referred to in UK law as ‘IP completion day’), key transitional arrangements come to
Interim injunctions—the American Cyanamid guidelinesThis Practice Note is concerned with substantive interim injunctions, which are a particular species of injunction granted on a temporary basis ahead of trial. As set out below, there are different considerations depending on whether the interim
Stay of proceedings—when can you apply to stay a claim?This Practice Note considers the question of when court proceedings can be stayed. It identifies scenarios in which a party may apply for a stay of proceedings, including to allow for: a jurisdictional challenge; arbitration; an attempt to
EL/PL claims in the portal—a practical guide (Stage 1)This Practice Note provides an overview of the Pre-Action Protocol for Low Value Personal Injury (Employers’ Liability and Public Liability) Claims from 31 July 2013 (the EL/PL protocol) in particular Stage 1 of the process. For guidance on Stage
0330 161 1234